Time to disability milestones and annualized relapse rates in NMOSD and MOGAD
Standard
Time to disability milestones and annualized relapse rates in NMOSD and MOGAD. / Duchow, Ankelien; Bellmann-Strobl, Judith; Friede, Tim; Aktas, Orhan; Angstwurm, Klemens; Ayzenberg, Ilya; Berthele, Achim; Dawin, Eva; Engels, Daniel; Fischer, Katinka; Flaskamp, Martina; Giglhuber, Katrin; Grothe, Matthias; Havla, Joachim; Hümmert, Martin W; Jarius, Sven; Kaste, Matthias; Kern, Peter; Kleiter, Ingo; Klotz, Luisa; Korporal-Kuhnke, Mirjam; Kraemer, Markus; Krumbholz, Markus; Kümpfel, Tania; Lohmann, Lisa; Ringelstein, Marius; Rommer, Paulus; Schindler, Patrick; Schubert, Charlotte; Schwake, Carolin; Senel, Makbule; Bergh, Florian Then; Tkachenko, Daria; Tumami, Hayrettin; Trebst, Corinna; Vardakas, Ioannis; Walter, Annette; Warnke, Clemens; Weber, Martin S; Wickel, Jonathan; Wildemann, Brigitte; Winkelmann, Alexander; Paul, Friedemann; Stellmann, Jan-Patrick; Häußler, Vivien; Neuromyelitis Optica Study Group (NEMOS).
In: ANN NEUROL, Vol. 95, No. 4, 04.2024, p. 720-732.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Time to disability milestones and annualized relapse rates in NMOSD and MOGAD
AU - Duchow, Ankelien
AU - Bellmann-Strobl, Judith
AU - Friede, Tim
AU - Aktas, Orhan
AU - Angstwurm, Klemens
AU - Ayzenberg, Ilya
AU - Berthele, Achim
AU - Dawin, Eva
AU - Engels, Daniel
AU - Fischer, Katinka
AU - Flaskamp, Martina
AU - Giglhuber, Katrin
AU - Grothe, Matthias
AU - Havla, Joachim
AU - Hümmert, Martin W
AU - Jarius, Sven
AU - Kaste, Matthias
AU - Kern, Peter
AU - Kleiter, Ingo
AU - Klotz, Luisa
AU - Korporal-Kuhnke, Mirjam
AU - Kraemer, Markus
AU - Krumbholz, Markus
AU - Kümpfel, Tania
AU - Lohmann, Lisa
AU - Ringelstein, Marius
AU - Rommer, Paulus
AU - Schindler, Patrick
AU - Schubert, Charlotte
AU - Schwake, Carolin
AU - Senel, Makbule
AU - Bergh, Florian Then
AU - Tkachenko, Daria
AU - Tumami, Hayrettin
AU - Trebst, Corinna
AU - Vardakas, Ioannis
AU - Walter, Annette
AU - Warnke, Clemens
AU - Weber, Martin S
AU - Wickel, Jonathan
AU - Wildemann, Brigitte
AU - Winkelmann, Alexander
AU - Paul, Friedemann
AU - Stellmann, Jan-Patrick
AU - Häußler, Vivien
AU - Neuromyelitis Optica Study Group (NEMOS)
N1 - This article is protected by copyright. All rights reserved.
PY - 2024/4
Y1 - 2024/4
N2 - OBJECTIVE: To investigate accumulation of disability in neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein-antibody-associated disease (MOGAD) in a changing treatment landscape. We aimed to identify risk factors for the development of disability milestones in relation to disease duration, number of attacks, and age.METHODS: We analyzed data from individuals with NMOSD and MOGAD from the German Neuromyelitis Optica Study Group registry. Applying survival analyses, we estimated risk factors and computed time to disability milestones as defined by the Expanded Disability Status Score (EDSS).RESULTS: We included 483 patients: 298 AQP4-IgG+ NMOSD, 52 AQP4-IgG-/MOG-IgG- NMOSD patients, and 133 patients with MOGAD. Despite comparable annualized attack rates, disability milestones occurred earlier and after less attacks in NMOSD patients than MOGAD patients (median time to EDSS 3: AQP4-IgG+ NMOSD 7.7 (95% CI 6.6-9.6) years, AQP4-IgG-/MOG-IgG- NMOSD 8.7) years, MOGAD 14.1 (95% CI 10.4-27.6) years; EDSS 4: 11.9 (95% CI 9.7-14.7), 11.6 (95% lower CI 7.6) and 20.4 (95% lower CI 14.1) years; EDSS 6: 20.1 (95% CI 16.5-32.1), 20.7 (95% lower CI 11.6), and 37.3 (95% lower CI 29.4) years; and EDSS 7: 34.2 (95% lower CI 31.1) for AQP4-IgG+ NMOSD). Higher age at onset increased the risk for all disability milestones, while risk of disability decreased over time.INTERPRETATION: AQP4-IgG+ NMOSD, AQP4-IgG-/MOG-IgG- NMOSD, and MOGAD patients show distinctive relapse-associated disability progression, with MOGAD having a less severe disease course. Investigator-initiated research has led to increasing awareness and improved treatment strategies appearing to ameliorate disease outcomes for NMOSD and MOGAD. ANN NEUROL 2024;95:720-732.
AB - OBJECTIVE: To investigate accumulation of disability in neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein-antibody-associated disease (MOGAD) in a changing treatment landscape. We aimed to identify risk factors for the development of disability milestones in relation to disease duration, number of attacks, and age.METHODS: We analyzed data from individuals with NMOSD and MOGAD from the German Neuromyelitis Optica Study Group registry. Applying survival analyses, we estimated risk factors and computed time to disability milestones as defined by the Expanded Disability Status Score (EDSS).RESULTS: We included 483 patients: 298 AQP4-IgG+ NMOSD, 52 AQP4-IgG-/MOG-IgG- NMOSD patients, and 133 patients with MOGAD. Despite comparable annualized attack rates, disability milestones occurred earlier and after less attacks in NMOSD patients than MOGAD patients (median time to EDSS 3: AQP4-IgG+ NMOSD 7.7 (95% CI 6.6-9.6) years, AQP4-IgG-/MOG-IgG- NMOSD 8.7) years, MOGAD 14.1 (95% CI 10.4-27.6) years; EDSS 4: 11.9 (95% CI 9.7-14.7), 11.6 (95% lower CI 7.6) and 20.4 (95% lower CI 14.1) years; EDSS 6: 20.1 (95% CI 16.5-32.1), 20.7 (95% lower CI 11.6), and 37.3 (95% lower CI 29.4) years; and EDSS 7: 34.2 (95% lower CI 31.1) for AQP4-IgG+ NMOSD). Higher age at onset increased the risk for all disability milestones, while risk of disability decreased over time.INTERPRETATION: AQP4-IgG+ NMOSD, AQP4-IgG-/MOG-IgG- NMOSD, and MOGAD patients show distinctive relapse-associated disability progression, with MOGAD having a less severe disease course. Investigator-initiated research has led to increasing awareness and improved treatment strategies appearing to ameliorate disease outcomes for NMOSD and MOGAD. ANN NEUROL 2024;95:720-732.
U2 - 10.1002/ana.26858
DO - 10.1002/ana.26858
M3 - SCORING: Journal article
C2 - 38086777
VL - 95
SP - 720
EP - 732
JO - ANN NEUROL
JF - ANN NEUROL
SN - 0364-5134
IS - 4
ER -